Kelly Seaton, Ph.D.
Affiliations: | 2009 | Pennsylvania State University, State College, PA, United States |
Area:
Pharmacology, Virology BiologyGoogle:
"Kelly Seaton"Mean distance: 42746.4
Parents
Sign in to add mentorJong K. Yun | grad student | 2009 | Penn State | |
(The human N-myristoyltransferases as potential pharmacotherapeutic targets in HIV-1 replication.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Walsh SR, Gay CL, Karuna ST, et al. (2024) A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087). Medrxiv : the Preprint Server For Health Sciences |
Reeves DB, Mayer BT, deCamp AC, et al. (2023) High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nature Communications. 14: 8299 |
Sobieszczyk ME, Mannheimer S, Paez CA, et al. (2023) Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial. The Lancet. Hiv. 10: e653-e662 |
Chirenje ZM, Laher F, Dintwe O, et al. (2023) Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120. The Journal of Infectious Diseases |
Tieu HV, Karuna S, Huang Y, et al. (2023) Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US. Vaccine |
Seaton KE, Huang Y, Karuna S, et al. (2023) Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. Ebiomedicine. 93: 104590 |
Huang Y, Zhang Y, Seaton KE, et al. (2022) Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens. Ebiomedicine. 84: 104271 |
Gilbert PB, Huang Y, deCamp AC, et al. (2022) Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nature Medicine |
Moodie Z, Dintwe O, Sawant S, et al. (2022) Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk. The Journal of Infectious Diseases |
Tomalka JA, Pelletier AN, Fourati S, et al. (2021) The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. Nature Immunology |